Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ITI will leverage Ichor’s TriGrid® Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM.
Lead Product(s): ITI-1001
Therapeutic Area: Oncology Product Name: ITI-1001
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Immunomic Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 16, 2020